维普中文期刊产品整合服务
9篇 您的检索式:作者名="Langenberg MH"
    题名 作者 年代 出处 被引量
1The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway显示文摘Roodhart JM Langenberg MH Witteveen E 2008Current Clinical Pharmacology2008,3,2:1
2The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway显示文摘Roodhart JM Langenberg MH Witteveen E 2008Curr Clin Pharmacol2008,3,:1
3Late release of circulating endothelial cells and endothelial progenitor cells after chemotherapy predicts response and survival in cancer patients显示文摘Roodhart JM Langenberg MH Vermaat JS 2010Neoplasia2010,12,1:1
4Translating pre- clinical findings of (endothelial) progenitor cell mobilization into the clinic; from bedside to bench and back显示文摘Roodhart JM Langenberg MH Daenen LG 2009Biochim Biophys Acta2009,1,:1
5Phase I evaluation of telatinib, a vascular endothelial growth factor recptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors显示文摘LANGENBERG MH WITFEVEEN PO ROODHART JM 2010Clin Cancer Res2010,16,7:1
6The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway显示文摘Roodhart JM Langenberg MH Witteveen E 2008Curr Clin Pharma- col2008,3,2:1
7The molecular basis of class side effects due to treatment with in- hibitors of the VEGF/VEGFR pathway显示文摘ROODHART JM LANGENBERG MH WITTEVEEN E 2008Curr Clin Pharma- col2008,3,2:1
8The molecularbasis of class side effects due to treatment with inhibitors of theVEGF/VEGFR pathway显示文摘Roodhart JM Langenberg MH Witteveen E 2008Curr Clin Pharmacol2008,3,2:1
9The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway显示文摘Roodhart JM Langenberg MH Witteveen E 2008Curr Clin Pharmacol2008,3,2:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费